The effects of new pharmaceutical composition containing Epigallocatechin-3-Gallate (EGCG) to inhibit methylation of the tumor supressor genes in patients with cervical intraepithelial neoplasia

• Published in: Vestnik Rossiĭskogo universiteta druzhby narodov. Serii͡a︡ Medit͡s︡ina no. 3; pp. 82 - 87
• Main Authors: I S Sidorova, A L Unanyan, V M Drukh, E L Muyzhnek
• Format: Journal Article
• Language: English
• Published: Peoples’ Friendship University of Russia (RUDN University) 01-12-2014
• Subjects: EGСG; метилирование генов; профилактика рака
• ISSN: 2313-0245; 2313-0261

Purpose: to develop preventive measures and reasonable therapy of pathological processes in the cervix uteri based on detection of methylation of tumor suppressor genes and groups at high-risk of cancer among patients of reproductive age with benign and premalignant cervical processes. Effectiveness of complex pathogenetic treatment of the cervix uteri has been evaluated in 127 women of reproductive age with benign and premalignant cervical processes before and after the combined treatment with a pharmaceutical composition containing active substance epigallocatechin-3-gallate (EGCG). Shown that pharmaceutical composition containing EGCG contributes demethylation of the tumor suppressor genes that confirm powerful oncoprotector action in treating precancerous lesions. One year after the complex combined therapy (including surgery) with pharmaceutical composition containing EGCG, recurrent cervical pathological processes have not been detected in patients with benign lesions, CIN I and CIN II.